Quick-Trials for Novel Cancer Therapies: Exploratory Grants (R21)
The summary for the Quick-Trials for Novel Cancer Therapies: Exploratory Grants (R21) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Quick-Trials for Novel Cancer Therapies: Exploratory Grants (R21): Continuing progress in basic cancer research and drug development has led to discoveries of new agents or approaches for molecular targeting in novel cancer therapies. These new agents or approaches suppress tumor growth through multiple mechanisms, such as: cell cycle control; activation of tumor suppressor genes; essential signal pathway blockage; tumor vaccines; tumor microenvironment modification; etc. Rapid translation of these exciting discoveries into clinical practice requires timely support to accommodate the special needs of novel cancer therapy development. This funding opportunity announcement (FOA) is intended to provide investigators with rapid access to support for pilot, Phase I, and Phase II cancer clinical trials as well as support for patient monitoring and laboratory studies linked to a cancer clinical trial. Phase III trials are not excluded, but such trials generally require greater resources and duration than available from an R21 grant award. Applications that do not propose a cancer clinical trial or patient monitoring or laboratory studies linked to a cancer clinical trial may be returned to applicants without being reviewed.
| Federal Grant Title: | Quick-Trials for Novel Cancer Therapies: Exploratory Grants (R21) |
| Federal Agency Name: | National Institutes of Health |
| Grant Categories: | Health Education |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | PAR-06-451 |
| Type of Funding: | Grant |
| CFDA Numbers: | 93.39393.394 |
| CFDA Descriptions: | Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research |
| Current Application Deadline: | No deadline provided |
| Original Application Deadline: | Multiple Receipt Dates - See Link to Full Announce |
| Posted Date: | Jun 09, 2006 |
| Creation Date: | Nov 19, 2007 |
| Archive Date: | Dec 20, 2007 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | $250,000 |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | 93.395 -- Cancer Treatment Research |
- Applicants Eligible for this Grant
- Others (see text field entitled "Additional Information on Eligibility" for clarification) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education City or township governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) Special district governments County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Additional Information on Eligibility
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply. Any individual with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applicants may submit more than one application, provided each application is scientifically distinct. However, the NIH will not accept similar grant applications with essentially the same research focus from the same applicant organization.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster